There is continual debate around which cancer drugs have the biggest improvement in QALYs and which are the best value for money. However, many cancer patients also suffer from major depression which has a huge impact on their lives, yet is frequently overlooked or ignored. Treating their depression would be a massive improvement in QALYs at a fraction of the cost of many drugs.
In a series of papers being published simultaneously across three Lancet journals researchers are reporting how common major depression is in people with different cancers, how frequently it is being overlooked, how best to treat it and what the impacts are for patients.
This briefing was held to discuss:
Prof Michael Sharpe, Professor of Psychological Medicine, University of Oxford
Dr Jane Walker, Senior Clinical Researcher, University of Oxford
Dr Stefan Symeonides, Clinical Lecturer in Medical Oncology, University of Edinburgh Cancer Research Centre
Prof Charlie Gourley, Professor of Medical Oncology and Honorary Consultant oncologist University of Edinburgh Cancer Research Centre